Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
GSDME-mediated target cell pyroptosis by CAR T cells activates macrophages to release proinflammatory cytokines for CRS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment for CRS and associated neurotoxicity primarily targets IL-6, likely arising from monocytes or activated endothelium [1, 6, 11–17].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [14]
In the citing paper
“Tumor lysis most likely also contributes to the cytokine storm through the induction of pyroptosis in target cells.55”
From Cytokine storm (2020) · cites this paper as [55]
Citations
Cites
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199
U.S. Department of Health and Human Services
(2006) · Encyclopedia of Sexual Behavior and the Law · doi:10.4135/9781452240107.n226 · Cited by 3,170
Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Shi, J., Gao, W., & Shao, F. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.10.004 · Cited by 3,088
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Pore-forming activity and structural autoinhibition of the gasdermin family
Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., Sun, H., Wang, D.-C., & Shao, F. (2016) · Nature · doi:10.1038/nature18590 · Cited by 2,771
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Cited by
Items 401–500 of 567
The conflicting role highlights the complexity of GSDMs in cancer
He, S., Huang, Q., & Cheng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1531695 · Cited by 12
“The release of pro-in fl ammatory cytokines during pyroptosis can exacerbate systemic in fl ammation, leading to cytokine release syndrome (CRS) or autoimmune-like responses (82).”
The Role of Mesenchymal Stem Cells in Cancer Immunotherapy
Zhao, Y., Zhong, X., Du, F., Wu, X., Li, M., Wen, Q., Shen, J., Chen, Y., Zhang, X., Yang, Z., et al. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230103120302 · Cited by 6
Self-citationA Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management
Teibo, J. O., Picanço‐Castro, V., de Souza, L. E. B., & Faça, V. M. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00930 · Cited by 7
Luo, Y., Li, J., Fu, Q., Zhang, P., Song, X., Liu, M., Mo, R., Fu, J., Tang, S., Wu, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96438-0 · Cited by 10
“Both granzyme B and caspase-3 utilise the cleavage of D270 to activate GSDME, leading to pyroptosis in tumour cells and enhancing anti-tumour immunity, exerting tumour-suppressive effects 23,42 .”
Self-citationGasdermins family-mediated cell survival: exploration of natural products intervention mechanisms
Zhang, W., Yan, J., Wang, Z., Zeng, Y., Sun, R., Hu, Q., Chen, Y., Ma, X., Zhao, Y., & Zeng, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157072 · Cited by 6
Self-citationZhang, X., Liang, H., Tang, Q., Chen, H., & Guo, F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.801665 · Cited by 5
Self-citationGuo, J., Yu, J., Mu, M., Chen, Z., Xu, Z., Zhao, C., Yang, K., Zheng, J., Xiao, Q., Zhao, W., et al. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2088570 · Cited by 5
“knocked out DFNA5 in lymphoma, breast cancer, and gastric cancer cell lines, and further found that the DFNA5 deficiency did not affect cancer cell growth [12].”
BackgroundAdvanced Therapy Medicinal Products
Neuhaus, V., Schaudien, D., & Dehmel, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_143 · Cited by 6
PROCR diminishes the efficacy of radiation by impairing T-cell-mediated antitumour immunity
Chen, W., Zhang, C., Li, Z., Xu, Z., Ding, C., Wu, J., Wei, H., Deng, Z., He, T., Long, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62558-4 · Cited by 5
Self-citationLi, Y., Liu, J., Luo, L., Zhou, L., Wu, Z., Sang, W., Jiang, H., Wang, X., Wang, X., Li, P., et al. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109527 · Cited by 5
Self-citationTian, L., Piao, S., Li, X., Guo, L., Huang, L., & Gao, W. (2025) · Advanced Science · doi:10.1002/advs.202500873 · Cited by 4
Therapeutic connections between pyroptosis and paclitaxel in anti-tumor effects: an updated review
Song, S., Wang, J., Ouyang, X., Huang, R., Wang, F., Xie, J., Chen, Q., & Hu, D. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04036-8 · Cited by 5
“Compared to natural T lymphocytes, chimeric antigen receptor (CAR) T cells exhibit superior tumor-targeting capabilities in triggering pyroptosis via the caspase-3/GSDME pathway, which is further facilitated by the release of granzyme B (GZMB) (Liu et al. 2020a).”
Self-citationYu, Z., Wang, L., Ji, C., Sun, Y., & Shao, F. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01103-2 · Cited by 5
Pyroptosis: the dawn of a new era in endometrial cancer treatment
Tian, P., Zhang, C., Chen, W., Zhao, X., Wu, W., Yang, W., & Liang, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1277639 · Cited by 4
Application of pyroptosis score in the treatment and prognosis evaluation of gastric cancer.
Li, L., & Ai-jun, L. (2023) · PubMed Central · doi:10.11817/j.issn.1672-7347.2023.230258 · Cited by 5
The role of extracellular vesicles in pyroptosis-mediated infectious and non-infectious diseases
Zhang, C., Lu, D.-C., Liu, Y., Wang, L., Sethi, G., & Ma, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112633 · Cited by 5
Self-citationA novel prognostic model based on pyroptosis signature in AML
Zhang, H., Zhu, H., Sheng, Y., Cheng, Z., & Peng, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36624 · Cited by 4
“In addition, CAR-T cell therapy for B-cell leukemia induces pyroptosis, leading to cytokine release syndrome [21].”
BackgroundPrognosis and immune features of pyroptosis-related RNA patterns in low-grade glioma
Liu, H., & Tao, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015850 · Cited by 4
“(66) reported that CAR-T cells activate the pyroptosis pathway of Caspase-3-GSDME by releasing GzmB, while co-culture experiments in vitro found that CAR-T can stimulate macrophages to release IL-6 and IL-1b by activating the Caspase-1-GSDMD pathway (67).”
BackgroundSun, T., Li, D., Huang, L., & Zhu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141779 · Cited by 6
“Pyroptosis is critical for CAR-T assassination of target cells and is proven to be the mechanism of CRS (86).”
BackgroundInsights Regarding the Role of Inflammasomes in Leukemia: What Do We Know?
Alves-Hanna, F. S., Crespo-Neto, J. A., Nogueira, G. M., Pereira, D. S., Lima, A. B., Pereira-Ribeiro, T. L., Santos, V. G. R., Fonseca, J. R. F., Magalhães-Gama, F., Sadahiro, A., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/5584492 · Cited by 6
Li, H., Huang, Q., & Zhang, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2291900 · Cited by 4
Self-citationEditorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy
Martín-Antonio, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666703 · Cited by 5
“The development of CRS and ICANS starts when CAR-T cells attack tumor cells initiating a type of inflammatory cell death termed pyroptosis which leads to release of pro-inflammatory mediators, such as IL1b, that will activate macrophages leading to a massive release of cytokines (4).”
BackgroundSPION-functionalized CAR-T cells: Overcoming key barriers in solid tumor therapy
Carnell, L. R., Alexiou, C., & Janko, C. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152770 · Cited by 3
Research progress on the role of mesenchymal stem cells in pyroptosis in sepsis
Xu, X., An, J., Yang, T., Li, B., & Dou, Z. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04837-x · Cited by 4
“Liu et al. demonstrated that chimeric antigen receptor T (CAR-T) cells induce pyroptosis in target cells by rapidly activating intracellular caspase-3 through the release of granzyme B, thereby triggering a caspase-3/ GSDME-dependent cell death pathway [48].”
Bidirectional role of neutrophils in lung cancer: Mechanisms and therapeutic implications
Wang, J., Zhang, M., Cui, Z., Qu, J., & Chang, R. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105087 · Cited by 3
GSDME in cardiovascular diseases: research system and contemporary progress
Yang, Z., Luo, Z., Zhang, H., Zong, J., Huang, P., Niu, Y., Zhou, C., Wang, S., & Zhang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1683116 · Cited by 3
Pyroptosis in Peripheral Neuropathy: From Molecular Mechanisms to Therapeutic Targeting
Wei, J., Liuyuan, M., Ye, Z., Wang, X., Zhou, X., Shan, Y., He, C., Zhu, C., Zhou, C., Bao, J., et al. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70760 · Cited by 3
“Beyond caspases, bacterial proteases (e.g., SpeB cleaving GSDMA) and granzymes (granzyme A [GzmA]/granzyme B [GzmB] cleaving GSDMB/GSDME, respectively) activate GSDMs, highlighting their role in host– pathogen interactions [11, 12, 71].”
Self-citationProgrammed cell death in lung cancer: mechanisms, immune responses, and therapeutics
Liu, Y., Chen, Q., Xu, J., & Chi, H. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02298-y · Cited by 5
Self-citationGuo, J., Cui, D., Tang, Y., Wang, S., Ma, C., & Ma, W. (2024) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2024.05.006 · Cited by 3
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
Nath, K., Wudhikarn, K., Tomás, A. A., & Perales, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2177268 · Cited by 3
Chen, H., Ding, B., Tan, J., Meng, Q., Li, J., Zhang, W., Zheng, P., Liu, B., Ma, P., & Lin, J. (2025) · Angewandte Chemie · doi:10.1002/ange.202501530 · Cited by 3
Non-coding RNAs modulate pyroptosis in diabetic cardiomyopathy: A comprehensive review
Shang, W., Geng, X., Sun, X., Fan, X., Li, A., Zhang, C., Kang, Y., Liang, Y., & Zhang, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142865 · Cited by 5
Chen, Z., Hu, Y., & Mei, H. (2024) · Pharmaceuticals · doi:10.3390/ph17010139 · Cited by 2
“Consequently, this process led to the simultaneous release of factors such as ATP and HMGB1, which activated the Caspase-1-gasdermin D (GSDMD) and MAPK-NF-κ B inflammatory pathways within macrophages, triggering an inflammatory factors storm [42].”
BackgroundSelf-citationHu, J., Feng, C., He, L., & Wang, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13578 · Cited by 6
“1) (45).”
Wang, J., Zhu, Q., Tong, G., Yu, K., Liang, J., Huang, Y., Wang, Y., Yang, C., Li, T., Liang, W., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02140-x · Cited by 3
“Huang et al. [19 ] confirmed that CAR-T cells activate caspase 3 in target cells, leading to pyroptosis via the caspase 3-GSDME axis, which causes severe side-effects such as cytokine release syndrome in CAR-T therapy patients.”
Zhao, J.-W., Li, L., Ye, F. C., & Zhao, W. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s531820 · Cited by 2
Wei, Q., Zhao, K., Wu, Y., Wu, W., & Hao, N. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70531 · Cited by 2
“40 These cytokines, including CCL5 and CXCL10, up-regulate tumour cell lysis via large amounts of granzyme B. 40,41 Collectively, the activation of the classical pathway results in immunosuppression against tumours.”
Ion overload-induced pyroptosis in nanoscale systems: A novel strategy for tumor immunotherapy
Wang, M., Ding, B., Ma, P., & Lin, J. (2026) · Precision medicine and engineering. · doi:10.1016/j.preme.2026.100055 · Cited by 2
CAR T Cell Toxicities and Emerging Treatment Strategies
Lulu, A. M., Steele, E., & Lee, D. W. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050224-120336 · Cited by 3
Guo, J., Liu, Y., Huang, Y., Liu, X., & Hu, Y. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02257-7 · Cited by 3
“…combined with GSDME-mediated tumor cell death, high mobility group box 1 (HMGB1) can activate caspase-1 and GSDMD in macrophages, triggering the release of IL-6, IL-18, and IL-1β, which may lead to cytokine release syn - drome (CRS) and reduce the effectiveness of T-cell therapy [ 109, 110].”
Self-citationXiong, J., Zhang, Y., Yu, Y., Yang, W., & Hu, Y. (2026) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.5c00737 · Cited by 2
Self-citationNKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions
Liu, C., Wang, Z., Zhang, W., Cheng, G., Cheng, S., Qin, L., Ye, H., & Ren, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1763843 · Cited by 5
Self-citationXu, Z., Li, Z. Z., Deng, Z., Ding, C., Wu, J., Zhang, C., Wei, H., He, T., Long, L., Tang, L., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01902-2 · Cited by 7
Self-citationYi, X., Yu, P., Wang, J., Fang, C., Ma, S., Li, K., Yan, R., Wang, G., Chen, Y., Chen, C., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01717-z · Cited by 2
Self-citationIschemia–Reperfusion Injury: Molecular Mechanisms and Therapeutic Interventions
An, P., An, Y., Chen, M., Wu, L., & Wang, R. (2026) · MedComm · doi:10.1002/mco2.70822 · Cited by 4
“By directly coupling membrane rupture with cytokine release, it functions as a central amplifier of tissue injury in IRI, making its key molecular nodes attractive targets for therapeutic intervention [ 125 ].”
Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure
Jawwad, T., Baba, S. K., Surendranath, A., Chaudhary, E., Jeelani, G., Akil, A. S. A.-S., Menhali, A. A., Bhat, A. A., & Mirza, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08584-2 · Cited by 2
“Treatments such as immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T) cells can produce deep and sometimes long-lasting responses by allowing immune cells to directly recognize and eliminate cancer cells [357–360].”
CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements
Li, C., Liu, Z., & Zhou, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1110 · Cited by 3
“Previous studies in the CD19-CAR-T study found that blocking IL-1 and IL-6 allowed for safer CAR-T cell immunotherapy, which was as well confirmed in the other antiaging research via uPAR-CAR-T [32, 33].”
BackgroundSelf-citationEnhancing the Treating Efficacy of Immunotherapy through the Restructure of Tumor Microenvironment
Gong, B., Jia, W., Zhou, Y., Xu, Y., Ya, W., & Gao, H. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300061 · Cited by 2
Self-citationMechanistic role of pyroptosis in tumor microenvironment and tumor immunotherapy
Attar, R., Qureshi, M. Z., Sabitaliyevich, U. Y., Yulaevna, I. M., & Romero, M. A. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.4.41 · Cited by 3
“Intraperitoneal injections of GSDME −/− NALM-6 or Raji cells in SCID-beige mice severely impaired CRS symptoms upon treatment with CAR T cells ( 91 ).”
BackgroundMethodMulticellular Cancer-Stroma Spheres (CSS) for In Vitro Assessment of CAR-T Cell-Associated Toxicity
Rakhmatullina, A. R., Zolotykh, M. A., Filina, Y. V., Valiullina, A. K., Zmievskaya, E., Gafurbaeva, D. U., Sagdeeva, A. R., Bulatov, E., Rizvanov, A. A., & Рифкатовна, М. Р. (2024) · Cells · doi:10.3390/cells13221892 · Cited by 2
Wang, R., Gao, F., Lingrui, H. A. O., Zhang, J., Zhexu, C. H. E. N., Song, D., Gao, F., He, W., Zhao, K., & Guan, J. (2025) · Journal of Veterinary Medical Science · doi:10.1292/jvms.24-0488 · Cited by 2
“…and other chemotherapeutic drugs depend on caspase3/GSDME activation-mediated pyroptosis of intestinal cells; the main reason for the systemic inflammatory storm caused by CAR-T therapy is also the extensive pyroptosis of lymphocytes induced by caspase-3/GSDME cleavage and activation [12 ].”
A Novel Pyroptosis-Related Prognostic Signature for Cervical Squamous Cell Carcinoma
Ou, T., Wei, Y., Long, Y., Pan, X., & Yao, D. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s353576 · Cited by 2
Marine-Derived Natural Product HDYL-GQQ-495 Targets P62 to Inhibit Autophagy
Li, Q., Fan, J., Chen, Y., Liu, Y., Liu, H., Jiang, W., Li, D., & Dang, Y. (2023) · Marine Drugs · doi:10.3390/md21020068 · Cited by 3
Self-citationGlycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
Qi, X., Li, J., & Luo, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1134174 · Cited by 4
Pyroptosis-related noncoding RNAs and cancer involvement
Chai, B., Qiu, J., Pan, W., & Ma, Z. (2023) · ONCOLOGIE · doi:10.1515/oncologie-2023-0045 · Cited by 3
Luo, Y., Li, J., Fu, Q., Zhang, P., Song, X., Liu, M., Mo, R., Fu, J., Tang, S., Wu, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4262020/v1 · Cited by 2
Self-citationMa, J., Xu, J., Gao, Q., Sun, Y., Wang, Y., Liu, Z., & Ma, Z. (2023) · Biotechnology Journal · doi:10.1002/biot.202200633 · Cited by 3
“[15] In cancer patients, GSDMEand lactate dehydrogenase (LDH) levels are correlated with severe CRS.[5] Therefore, pyroptosis participates in various diseases, as evidenced by the activation of inflammatory CASPs, increased cleavage of GSDMD or GSDME, and substantial release of IL-1β.”
BackgroundSelf-citationLi, Z., Hu, B., & Zou, X. (2024) · Perioperative Precision Medicine · doi:10.61189/434706ysltap · Cited by 1
Cheng, W., Chen, W., & Jia, R. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s487740 · Cited by 1
“54 In contrast, chimeric antigen receptor (CAR) T cell-derived GzmB can induce pyroptosis both through the activation of caspase-3 and via direct cleavage of GSDME 55,56 (Figure 1).”
InfluentialHe, H., & Zhao, D. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102185 · Cited by 1
Therapeutic approaches for liver fibrosis/cirrhosis by targeting pyroptosis
Qiao, G., Li, P., Wang, M., Li, C., Wang, Y., Xin, S., & Liu, H. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1092 · Cited by 3
“In 2020, granzyme B was found to activate caspase-3 to cleave gasdermin family protein E (GSDME), resulting in extensive pyroptosis [24].”
From mechanisms to markers: role of pyroptosis in revolutionizing thyroid cancer care
Wang, N., Chen, Y., Luo, G., & Luo, D. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02741-0 · Cited by 2
“Research has demonstrated that chimeric antigen receptor T cells can initiate the activation of caspase-3 in target cells through the release of granzyme B, which subsequently cleaves GSDME and results in extensive pyroptosis [76].”
H6N6 Avian Influenza Virus Infection Induced Pyroptosis of M1 Macrophages by Activating Caspase-1
Zhu, H., He, D., Liu, S., Fan, X., Gao, L., Guo, L., & Zhang, Z. (2025) · Viruses · doi:10.3390/v17111492 · Cited by 1
“Pyroptosis can be divided into the canonical pathway, the non-canonical pathway, the caspase-3/8– mediated pathway, and the granzyme-mediated pathway [15–21].”
Self-citationWu, D., Zhang, Y., Guo, Y., & Dong, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117587 · Cited by 3
Self-citationResearch progress on pyroptosis regulated by mesenchymal stem cell-derived exosomes
Yang, T., An, J., Xu, X., Li, B., & Dou, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1717465 · Cited by 5
“Notably, several studies have revealed that granzyme A (GzmA) and GzmB can cleave GSDMB and GSDME, respectively, to produce active GSDMB/E-NT fragments (38, 47, 48).”
Harnessing pyroptosis to restrain melanoma through aripiprazole
Chang, Y.-T., Lin, I.-H., Shieh, J., Lan, T., Syu, J., Huang, S. R., & Hou, P. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02223-9 · Cited by 1
SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma
Jiao, Q., Ren, Y., Su, X., Li, Z., Cai, Y., Hu, T., Wang, Y., Zhang, G., Zhao, M., & Feng, M. (2026) · Oncogene · doi:10.1038/s41388-026-03759-z · Cited by 1
Wu, J., Li, D., Mei, H., & Hu, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117949 · Cited by 1
Self-citationLi, J., Li, Z., Wang, P., & Jiang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1704424 · Cited by 1
Blumenberg, V., Diorio, C. J., Gauthier, J., Agrusa, J. E., Dreyzin, A., Hänel, G., Espinoza-Gutarra, M. R., Geer, M. J., Perales, M., Ramakrishna, S., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.005 · Cited by 2
Yang, Y., Sun, Y., Kang, H., Guan, E., Liu, R., Yang, K., & Jiang, D. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08299-4 · Cited by 1
“However, pyrop-tosis can exacerbate the severity of CRS [92].”
Regulated cell death programs shaping cancer therapy
Luo, H., & Guo, Y. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01232-3 · Cited by 1
“For instance, in CAR T-cell therapy, GSDME-mediated tumor cell pyroptosis can trigger a cascade of macrophage activation and cytokine release syndrome [131].”
Qiao, X., Ye, T., Wu, T., Han, X., Sun, T., Wang, H., Jia, J., Dai, Y., Yun, R., Jiang, S., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02324-z · Cited by 2
“Targeting GSDME can also convert apoptosis into pyroptosis [635 ].”
Wei, X., Jiang, Y., Li, Z., Hu, J., Chenwu, F., Li, F., Song, M., He, Y., & Wang, J. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218178 · Cited by 2
Karimi, S., Dehpour, A. R., Hadjighassem, M., Khajehnasiri, A., Atef‐Yekta, R., aghaei, M., Majedi, H., & Hosseindoost, S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102982 · Cited by 1
“54 The expression of GSDMB, unlike other GSDMs, in HEK293T cells induces pyroptotic cell death mediated by NK cells.”
Xu, L., Wu, H., Wu, C., & Xu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108316 · Cited by 3
Yang, T.-L., Zhong, H., Wang, W., & Wang, J. (2022) · Chinese Medical Sciences Journal · doi:10.24920/004167 · Cited by 1
Liu, Y., Li, N., Jiang, W., & Geng, Q. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.02 · Cited by 1
Self-citationAdvanced Therapy Medicinal Products
Neuhaus, V., Schaudien, D., & Dehmel, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_143-1 · Cited by 1
Wei, K.-K., Du, Z.-X., Deng, J., Yang, J.-W., & Chen, H. (2023) · Journal of Immunology Research · doi:10.1155/2023/8776892 · Cited by 1
“In the granzyme proteases mediated pathway, the granzyme B produced by T cells or natural killer cells (NKs) leads to the target cell pyroptosis by direct cleavage of GSDME [31, 32].”
BackgroundCytokine storm in COVID-19 and other diseases: emerging therapeutic interventions
Sahu, S., Dharra, R., Gun, M., Datta, S., Akela, A. K., & Kumar, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95545-4.00018-9 · Cited by 1
Zinc Suppresses Colorectal Cancer Development through Cell-mediated Immunity
Nishida, K., & Nakagawa, N. (2024) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.23-00154-1 · Cited by 1
Wang, Y., Li, D., Xun, J., He, Y., & Wang, H. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i7.2281 · Cited by 1
Osteosarcoma biomarker analysis and drug targeting prediction based on pyroptosis-related genes
Zhuang, Y., & Li, X. (2025) · Medicine · doi:10.1097/md.0000000000040240 · Cited by 1
Mechanisms of pyroptosis in vitiligo
Geng, Y., Huang, P., & Cui, T. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103081 · Cited by 2
Yang, W., Huang, X., Zhang, Y., Tian, Y., Pan, T., Guo, Y. C., Dong, J., & Li, L. (2022) · Research Square · doi:10.21203/rs.3.rs-2185352/v1 · Cited by 1
Self-citationWang, Q., Hu, X., Yin, H., Chen, T., Xie, D., Li, Y., Zheng, H., & Lu, M. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-t4ll1 · Cited by 1
CD19 occupancy may drive CARs further
Hirayama, A. V. V., & Bleakley, M. (2024) · Blood · doi:10.1182/blood.2023022783 · Cited by 1
Atomic force microscopy: dancing on the stage of immunology
Huang, B. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00664-1
“Using AFM, it was observed that many pores were formed in the membrane of B leukemic cells after coculture with CD19-CAR T cells, thus leading to leukemic cell pyroptosis and subsequent triggering of cytokine release syndrome.(5) During the interaction of T cells and tumor cells, T cells release perforin to form pores…”
BackgroundSelf-citationJin, Y., & Xue-song, B. (2021) · Research Square · doi:10.21203/rs.3.rs-1020197/v1
yunshan, W., Ren, Y., Feng, M., Liu, X., Hao, X., Li, J., Li, P., Gao, J., Qi, Q., Du, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1046804/v1 · Cited by 1
Immunotherapies and their moderation
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00006-9
GSDME with a moonlighting function in pancreatic ductal adenocarcinoma: a narrative review
Huang, B. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000104
“Such mechanistic identification suggests that GSDME might be a possible target for CRS prevention.[47] Regarding this pore formation-induced pyroptosis, GSDME has been explored in tumor immunotherapy, based on that GSDME-mediated tumor cell pyroptosis may arouse antitumor immune responses.”
BackgroundSelf-citationApoptosis and inflammasome regulation
Brož, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00032-3 · Cited by 2
Cytokine release syndrome after CAR T-cell therapy: a review of the literature and our experience
Čemusová, B. (2022) · Anesteziologie a intenzivní medicína · doi:10.36290/aim.2022.013
Luan, R., & Deng, B. (2023) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0009
Data from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Ren, Y., Feng, M., Hao, X., Liu, X., Li, J., Li, P., Gao, J., Qi, Q., Du, L., Wang, C., et al. (2023) · doi:10.1158/0008-5472.c.6487386.v2
Song, M., Zhu, Z., Geng, Q., Chen, B., & Cao, G. (2023) · Research Square · doi:10.21203/rs.3.rs-2832419/v1
Pyroptosis-related genes expression and nomogram predict overall survival of gastric cancerPreprint
Wang, S., Li, X.-C., Zhu, J.-R., Ran, J.-T., & Guan, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-2993160/v1
Metadata
- Authors
- Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., Xie, J., Gao, Y., Cheng, F., Zhou, Y., Zhang, Z., Hu, Y., Zhang, X., Gao, Q., Zhang, Y., & Huang, B.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Huazhong University of Science and Technology (CN)
- Wuhan Union Hospital (CN)
- Peking University People's Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Liu, Yuying
- Fang, Yiliang
- Chen, Xinfeng
- Huang, Bo
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2999534343
- Cited by
- 566
- References
- 45
- Citations by year
- 2026: 63 · 2025: 87 · 2024: 100 · 2023: 127 · 2022: 96 · 2021: 70 · 2020: 22
- FWCI
- 28.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81788101, 81661128007, 81530080, 81773062)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- gasdermin E, pyroptosis, chimeric antigen receptor T cells, cytokine release syndrome, macrophage activation, inflammatory cytokines, target cell death, adoptive T cell therapy
- MeSH terms
- Pyroptosis, Cytokine Release Syndrome, Gasdermins, Animals, Female, Humans, Macrophages, T-Lymphocytes, Leukemia, B-Cell, Immunotherapy, Adoptive, Phosphate-Binding Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Mice, Granzymes, Perforin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.